WO2017123030A1 - 로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 갱년기 증후군 예방, 개선 또는 치료용 조성물 - Google Patents
로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 갱년기 증후군 예방, 개선 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2017123030A1 WO2017123030A1 PCT/KR2017/000438 KR2017000438W WO2017123030A1 WO 2017123030 A1 WO2017123030 A1 WO 2017123030A1 KR 2017000438 W KR2017000438 W KR 2017000438W WO 2017123030 A1 WO2017123030 A1 WO 2017123030A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preventing
- female
- loganin
- menopausal
- estrogen
- Prior art date
Links
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 title claims abstract description 26
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 title claims abstract description 26
- 239000004480 active ingredient Substances 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 6
- 229940011871 estrogen Drugs 0.000 claims abstract description 35
- 239000000262 estrogen Substances 0.000 claims abstract description 35
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 29
- 230000007423 decrease Effects 0.000 claims abstract description 19
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims abstract description 18
- 102100038595 Estrogen receptor Human genes 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 235000013402 health food Nutrition 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 102000016267 Leptin Human genes 0.000 claims description 8
- 108010092277 Leptin Proteins 0.000 claims description 8
- 208000026139 Memory disease Diseases 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 6
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 5
- 206010065941 Central obesity Diseases 0.000 claims description 5
- 208000000044 Amnesia Diseases 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 208000033830 Hot Flashes Diseases 0.000 claims description 4
- 206010060800 Hot flush Diseases 0.000 claims description 4
- 206010033557 Palpitations Diseases 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- 208000002173 dizziness Diseases 0.000 claims description 4
- 230000006984 memory degeneration Effects 0.000 claims description 4
- 208000023060 memory loss Diseases 0.000 claims description 4
- 230000027939 micturition Effects 0.000 claims description 4
- 230000035900 sweating Effects 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000006820 Arthralgia Diseases 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 206010029216 Nervousness Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010068313 Urethral atrophy Diseases 0.000 claims description 3
- 206010046764 Uterine atrophy Diseases 0.000 claims description 3
- 206010046914 Vaginal infection Diseases 0.000 claims description 3
- 201000008100 Vaginitis Diseases 0.000 claims description 3
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 230000037336 dry skin Effects 0.000 claims description 3
- 206010013990 dysuria Diseases 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000006403 short-term memory Effects 0.000 claims description 3
- 231100001042 uterine atrophy Toxicity 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract description 18
- 210000001789 adipocyte Anatomy 0.000 abstract description 17
- 238000010172 mouse model Methods 0.000 abstract description 16
- 210000004291 uterus Anatomy 0.000 abstract description 16
- 210000000579 abdominal fat Anatomy 0.000 abstract description 15
- 229960005309 estradiol Drugs 0.000 abstract description 13
- 238000009825 accumulation Methods 0.000 abstract description 11
- 229930182833 estradiol Natural products 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 8
- 230000007850 degeneration Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000004584 weight gain Effects 0.000 abstract description 7
- 235000019786 weight gain Nutrition 0.000 abstract description 7
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 abstract description 6
- 230000004580 weight loss Effects 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 26
- 229940088597 hormone Drugs 0.000 description 18
- 239000005556 hormone Substances 0.000 description 18
- 230000009245 menopause Effects 0.000 description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 230000002611 ovarian Effects 0.000 description 9
- AMBQHHVBBHTQBF-DLXIZZNVSA-N methyl 6-hydroxy-7-methyl-1-[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate Chemical compound C12C(C)C(O)CC2C(C(=O)OC)=COC1O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O AMBQHHVBBHTQBF-DLXIZZNVSA-N 0.000 description 8
- 229960003387 progesterone Drugs 0.000 description 8
- 239000000186 progesterone Substances 0.000 description 8
- 101100496858 Mus musculus Colec12 gene Proteins 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 229940039781 leptin Drugs 0.000 description 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 2
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 108010006989 estrone receptor Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- -1 patch Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 0 C*C([C@]1C(O)=C(OC[C@@]2OC=C(C)C[C@@]2(C)[C@@](C)[C@](CC=N)O)OC2CO)C12OC Chemical compound C*C([C@]1C(O)=C(OC[C@@]2OC=C(C)C[C@@]2(C)[C@@](C)[C@](CC=N)O)OC2CO)C12OC 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001113846 Loganiaceae Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical group 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a composition for preventing, ameliorating, or treating female menopausal syndrome, which contains loganan, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- Estrogen a representative hormone that symbolizes women, is an important female hormone that regulates the life of a woman from menstruation, pregnancy, and menopause.
- Estrogen is well known as a female hormone secreted mainly in the follicles, corpus luteum, and placenta in women's ovaries.
- Estrogens collectively include hormones such as estrone (E1), estradiol (E2), and estriol (E3). Of these, estradiol (E2) shows the strongest activity among estrogens.
- FSH Follicle Stimulating Hormone
- Estrogens used in the body are transformed into structures suitable for excretion by the liver and then released through urine.
- progesterone is also regulated by luteinizing hormone, and because it is closely related to estrogen, an appropriate balance of estrogen and progesterone is important.
- Estrogens affect a wide range of tissues and organs, from the brain to the liver and bones, and estrogens are needed especially for the uterus, urinary system, breasts, skin, and blood vessels to maintain flexibility and steady state (Figure 1).
- Women's menopause also called menopause, refers to the transition from maturity as a woman to old age due to ovarian function.
- the age of menopause varies depending on constitution, nutritional status, and the number of deliveries. Prolonged life expectancy tends to be slightly later in menopause.
- Menopause begins at the perimenopause period when the amount of estrogen begins to decrease, and during menopause, about 12 months when estrogen and progesterone production is very low, menstruation is completely stopped, and menstruation is completely stopped. Since then it is the time of postmenopause (Fig. 2).
- ovarian function decreases and ataxia decreases the female hormone secreted from the ovary, resulting in various symptoms.
- Periods of menstruation, menstrual periods, and menstrual periods are irregular, and hot flashes appear mainly on the face and upper body, sweating and chest palpitations, and the vulva are dry and vaginal mucus is reduced.
- Atrophy of the urine which can lead to an increase in the number of urine or pain during urination.
- Other symptoms may include dizziness, tinnitus, high blood pressure, digestive problems, headaches, sleep disorders, memory loss, cognitive dysfunction, mood changes, and depression.
- estrogen is involved in stimulating and developing muscles in the uterus, a marked decrease in the estrogen receptor of uterine tissue cells is shown by estrogen reduction.
- Estrogen receptors are activated by estradiol (E2), and there are two types of estrogen receptor alpha and estrogen receptor beta. In the womb, estrone receptor alpha plays a more important role than beta. In menopause, a significant decrease in estrogen receptor alpha causes uterine contractions and degeneration. In addition, new estrogens are produced from adipocytes of adipose tissue to offset estrogen deficiency. In this process, more fat cells are produced, which may cause abdominal obesity (FIG. 3).
- the present invention provides a pharmaceutical composition for preventing or treating female menopausal syndrome, which contains Loganin, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a health food composition for preventing or ameliorating female menopausal syndrome, which contains Loganin, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention relates to a composition for preventing, ameliorating, or treating female menopausal syndrome, which contains loganan, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- Increases estradiol (17 ⁇ -estradiol, E2) levels in the blood increases expression of estrogen receptor alpha in the uterus, improves uterine contraction and degeneration, and accumulates and enlarges adipocytes in liver and abdominal adipose tissue Efficacy in terms of weight loss, weight loss, and the like.
- loganin has the effect of ameliorating the symptoms of decreased estrogen, weight gain, fat accumulation and fat cell size in liver and abdominal adipose tissue in menopausal women. Therefore, it is expected that the lignin and the composition containing the same as an active ingredient of the present invention can be usefully used as a pharmaceutical preparation for preventing and improving menopausal symptoms.
- Figure 4 shows the types and symptoms of female menopausal syndrome symptoms.
- Figure 5 shows the chemical structural formula of logannin.
- FIG. 6 shows the serum of the female hormone estradiol (E2) (FIG. 6A) and progesterone after 12 weeks of administration of 10 mg / kg / day of rogannine in a menopausal mouse model (ovary-extracted mouse). (FIG. 6B), which indicates that loganan is significantly effective in suppressing menopausal female hormone reduction.
- FIG. 7 is a 12-week post-administration of 10 mg / kg / day of rogannine in a menopausal mouse model to extract the uterus of the mouse and express the mRNA expression level of the estrogen receptor alpha gene (FIG. 7A) and immunohistochemistry of the uterine cutting plane.
- FIG. 7b As a result of analyzing the amount of estrogen receptor alpha protein expression (FIG. 7b), it is shown that loganan is significantly effective in suppressing the decrease of estrogen receptor alpha expression level in uterine tissue cells by menopause.
- FIG. 8 is a 12-week post-administration of rogannine 10 mg / kg / day in the menopausal mouse model, and a picture of the uterus extracted from the mouse (FIG. 8A), a picture of H & E staining of the uterine section (FIG. 8B), and the weight of the uterus (FIG. 8c) shows that loganin is significantly effective in suppressing uterine contractions and degeneration by menopause.
- FIG. 9 is a 12-week post-administration of 10 mg / kg / day of loganine in a menopausal mouse model to measure the body weight of the mouse (FIG. 9A) and to separate serum from the mouse blood, insulin (insulin) and leptin, which are fat metabolism-related hormones.
- insulin insulin
- leptin leptin
- FIG. 10 is a result of H & E staining of the liver (FIG. 10A) and abdominal adipose tissue (FIG. 10B) after 12 weeks of administration of 10 mg / kg / day of loganine to the menopausal mouse model.
- the present inventors have investigated the in vivo efficacy of a single compound, a compound that is effective for reducing estrogen hormone in menopausal women and weight gain and improvement of fat accumulation and fat cell size in liver and abdominal adipose tissue. And the present invention was completed.
- the present invention provides a pharmaceutical composition for preventing or treating female menopausal syndrome, which contains Loganin, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the female menopausal syndrome is caused by a decrease in estrogen secretion
- the decrease in estrogen secretion reduces the amount of estrogen receptor alpha expression of uterine tissue cells, blood insulin and leptin protein Can be increased.
- the female climacteric syndrome is hot flashes, sweating, insomnia, nervousness, depression, dizziness, lack of concentration, short-term memory disorders, anxiety, memory loss, palpitations, myalgia, joint pain, dry skin, vaginal dryness, vaginal atrophy, Lower urethral atrophy, vaginitis, uterine atrophy, cystitis, urination pain, urination, abdominal obesity, hyperlipidemia, arteriosclerosis or fatty menopausal symptoms, but is not limited thereto.
- Loganin of the present invention is represented by the formula (1), the molecular formula is C 17 H 26 O 10 .
- the pharmaceutically acceptable salt is an organic acid selected from the group consisting of oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid and benzoic acid, or an inorganic acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid and hydrobromic acid. It may be an acid addition salt formed by.
- the pharmaceutical composition may be formulated as a cream, gel, patch, spray, ointment, warning, lotion, linen, pasta and cataplasma.
- the pharmaceutical composition may include a pharmaceutically acceptable carrier in addition to the Loganin, such a pharmaceutically acceptable carrier is commonly used in pharmaceutical formulations, lactose, dextrose, Sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl Hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, but are not limited thereto.
- the pharmaceutical composition may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent,
- the pharmaceutical composition is determined according to the degree of symptoms of menopausal syndrome, the method of administration is usually preferred.
- the dosage of the active ingredient in the pharmaceutical composition may vary depending on the route of administration, the degree of the disease, the age, sex, and weight of the patient, and may be administered once to several times daily.
- the present invention provides a health food composition for preventing or ameliorating female menopausal syndrome, which contains Loganin, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the health food composition may be provided in the form of a powder, granules, tablets, capsules, syrups, beverages or pills, wherein the health food composition is in addition to other foods or food additives other than loganan (Loganin) according to the present invention as an active ingredient It can be used together and appropriately used according to a conventional method.
- the mixed amount of the active ingredient can be suitably determined depending on the purpose of use thereof, for example, prophylactic, health or therapeutic treatment.
- An effective dose of Loganin contained in the health food composition may be used in accordance with the effective dose of the pharmaceutical composition, but in the case of long term intake for health and hygiene purposes or for health control purposes, It may be less than the above range, it is clear that the active ingredient can be used in an amount above the above range because there is no problem in terms of safety.
- Loganin is an iridoid glycosides of the name Derived from the Loganiaceae, the chemical formula is C 17 H 26 O 10 (Fig. 5). Loganin is a naturally occurring single compound that is found in horses (nux vomica) and cornus officinalis.
- ovaryctomized ddY female mouse (ovariectomized-mouse, OVX mouse) was used as a menopausal animal model.
- OVX mice group (open control) without ovarian ablation (normal control group)
- OVX mice group (negative control group) that received physiological saline only in ovarian ablation mice
- SrCl 2 strontium chloride
- 10-week-old sham-operated and ovarian abdominal ddY female mice were purchased from Central Experimental Animal Co., Ltd. and moved to a clean animal breeding area after 1 week of acclimation in the Quarantine Office of Ajou University. The weight of each mouse was measured, and group separation was performed so that there was no statistically significant weight difference between the experimental groups.
- Loganin to be used in the experiment was made of a test solution in an aqueous solution, and the sterilization operation was performed by gamma irradiation to the Soya Greentec Co., Ltd., a radiation irradiation company for the import of experimental animal center.
- test group was orally injected with loganine at a dose of 10 mg / kg / day for 12 weeks to determine blood estrogen levels, expression levels of estrogen receptor alpha in uterine tissue, uterine size, weight, and fat cell size in liver and abdominal adipose tissue. Measurement and analysis were performed.
- a common female menopausal symptom is a marked decrease in the female hormones estrogen and progesterone.
- Blood levels of estrogens estradiol (17 ⁇ -estradiol, E2) and progesterone were measured using the ELISA method after 12 weeks of administration of loganin to female menopausal mouse models.
- female hormones estradiol (FIG. 6A) and progesterone (FIG. 6B) were significantly reduced in OVX mice without ovaries.
- SrCl 2 a group of ineffective compound administration Mice did not differ from OVX mice.
- a common female menopausal symptom is a marked decrease in the estrogen receptor of uterine tissue cells due to estrogen reduction.
- Estrogen receptors are activated by estradiol (E2), and there are two types of estrogen receptor alpha and estrogen receptor beta.
- E2 estradiol
- estrone receptor alpha plays a more important role than beta.
- menopause a significant decrease in estrogen receptor alpha causes uterine contractions and degeneration. Twelve weeks after the administration of Loganin to a female menopausal mouse model, mouse uterus was extracted and analyzed for mRNA expression of estrogen receptor alpha gene and expression of estrogen receptor alpha protein by immunohistochemistry of the uterine cleavage.
- FIG. 7A Compared to normal Shame mice without ovaries, the mRNA expression level of estrogen receptor alpha (FIG. 7A) and protein amount (FIG. 7B) were significantly decreased in OVX mice without ovaries. SrCl 2, a group of ineffective compound administration Mice did not differ from OVX mice. However, in the loganin-administered group, the mRNA expression level of estrogen receptor alpha and the decrease of estrogen receptor alpha protein were significantly suppressed (FIGS. 7A and 7B). The significance of the efficacy was also confirmed in the statistical analysis (*: p ⁇ 0.05 vs. OVX negative control).
- Common menopausal symptoms include contraction and degeneration of the uterus due to estrogen reduction. Twelve weeks after the administration of Loganin to a female menopausal mouse model, the uterus of the mouse was extracted and the shape, size, thickness, and weight of the uterus were observed. Compared to normal Shame mice without ovarian removal, the uterine ovary-deleted OVX mice had a small uterus (FIG. 8A), a thin section thickness (FIG. 8B), and a light weight of the uterus (FIG. 8C). SrCl 2, a group of ineffective compound administration Mice did not differ from OVX mice.
- a common female climacteric symptom is weight loss due to estrogen reduction.
- the body weight and metabolism-related hormone proteins, insulin and leptin were measured by ELISA.
- the body weight of OVX mice without ovary (FIG. 9A) was significantly increased, and the amount of insulin (FIG. 9B) and leptin (FIG. 9C) was increased.
- Non-efficacy compared to compound administration soldier SrCl 2 Mice did not differ from OVX mice. However, in the loganin-administered group, the weight gain of the mice was significantly suppressed (FIG.
- Example 6 female menopausal mouse model Loganine Improvement of fat accumulation in liver and fat cell size increase in abdominal adipose tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (7)
- 로가닌(Loganin), 이의 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 여성 갱년기 증후군 예방 또는 치료용 약학조성물.
- 제1항에 있어서, 상기 여성 갱년기 증후군은 에스트로겐 분비 저하에 의한 것을 특징으로 하는 여성 갱년기 증후군 예방 또는 치료용 약학조성물.
- 제2항에 있어서, 상기 에스트로겐 분비 저하는 자궁조직세포의 에스트로겐 수용체 알파(estrogen recepotr alpha) 발현량을 감소시키고, 혈중 인슐린(insulin) 및 렙틴(leptin) 단백질을 증가시키는 것을 특징으로 하는 여성 갱년기 증후군 예방 또는 치료용 약학조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 여성 갱년기 증후군은 안면홍조, 발한, 불면증, 신경과민, 우울증, 현기증, 집중력 결핍, 단기 기억장애, 불안, 기억력 감퇴, 심계항진, 근육통, 관절통, 피부건조, 질건조증, 질위축, 하부 요도 위축, 질염, 자궁위축, 방광염, 배뇨통, 급뇨, 복부비만, 고지혈증, 동맥경화 및 지방간으로 이루어진 군에서 선택된 어느 하나 이상의 갱년기 증상인 것을 특징으로 하는 여성 갱년기 증후군 예방 또는 치료용 약학조성물.
- 로가닌(Loganin), 이의 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 여성 갱년기 증후군 예방 또는 개선용 건강식품 조성물.
- 제5항에 있어서, 상기 여성 갱년기 증후군은 안면홍조, 발한, 불면증, 신경과민, 우울증, 현기증, 집중력 결핍, 단기 기억장애, 불안, 기억력 감퇴, 심계항진, 근육통, 관절통, 피부건조, 질건조증, 질위축, 하부 요도 위축, 질염, 자궁위축, 방광염, 배뇨통, 급뇨, 복부비만, 고지혈증, 동맥경화 및 지방간으로 이루어진 군에서 선택된 어느 하나 이상의 갱년기 증상인 것을 특징으로 하는 여성 갱년기 증후군 예방 또는 개선용 건강식품 조성물.
- 제5항에 있어서, 상기 건강식품은 정제, 캡슐, 분말, 과립, 액상 및 환으로 이루어진 군에서 선택된 어느 하나의 형태를 갖는 것을 특징으로 하는 여성 갱년기 증후군 예방 또는 개선용 건강식품 조성물.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3021083A CA3021083C (en) | 2016-01-13 | 2017-01-13 | Composition, containing loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome |
EP17738659.6A EP3403656B1 (en) | 2016-01-13 | 2017-01-13 | Composition, containing loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome |
AU2017206480A AU2017206480B2 (en) | 2016-01-13 | 2017-01-13 | Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome |
RU2018128198A RU2697672C1 (ru) | 2016-01-13 | 2017-01-13 | Композиция для предупреждения, облегчения или лечения климактерического синдрома у женщин, содержащая логанин или его производные в качестве активного ингредиента |
JP2018556775A JP6818047B2 (ja) | 2016-01-13 | 2017-01-13 | ロガニンまたはその誘導体を有効成分として含有する女性更年期症候群の予防、改善または治療用組成物 |
US16/069,522 US11116781B2 (en) | 2016-01-13 | 2017-01-13 | Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome |
BR112018014254-9A BR112018014254A2 (ko) | 2016-01-13 | 2017-01-13 | A composition for preventing, improving or treating female menopausal syndrome comprising rogannin or a derivative thereof as an active ingredient |
CN201780016721.3A CN109069524A (zh) | 2016-01-13 | 2017-01-13 | 用于预防、补救或治疗雌性更年期综合征的包含马钱苷或其衍生物作为活性成分的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160004169A KR101698051B1 (ko) | 2016-01-13 | 2016-01-13 | 로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 갱년기 증후군 예방, 개선 또는 치료용 조성물 |
KR10-2016-0004169 | 2016-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017123030A1 true WO2017123030A1 (ko) | 2017-07-20 |
Family
ID=57989630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/000438 WO2017123030A1 (ko) | 2016-01-13 | 2017-01-13 | 로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 갱년기 증후군 예방, 개선 또는 치료용 조성물 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11116781B2 (ko) |
EP (1) | EP3403656B1 (ko) |
JP (1) | JP6818047B2 (ko) |
KR (1) | KR101698051B1 (ko) |
CN (1) | CN109069524A (ko) |
AU (1) | AU2017206480B2 (ko) |
BR (1) | BR112018014254A2 (ko) |
CA (1) | CA3021083C (ko) |
RU (1) | RU2697672C1 (ko) |
WO (1) | WO2017123030A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107485617A (zh) * | 2017-08-08 | 2017-12-19 | 中日友好医院 | 马钱苷在制备治疗或缓解疼痛的药物和保健品中的应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106176789A (zh) * | 2016-06-23 | 2016-12-07 | 中日友好医院 | 马钱苷在制备预防和治疗抑郁症、焦虑症等精神障碍类疾病药物或保健品中的应用 |
KR101877443B1 (ko) * | 2017-11-08 | 2018-07-11 | 아주대학교산학협력단 | 로가닉산 또는 이의 유도체를 유효성분으로 함유하는 비만 예방, 개선 또는 치료용 조성물 |
KR102282391B1 (ko) * | 2019-12-12 | 2021-07-27 | 가톨릭대학교 산학협력단 | 로가닌을 유효성분으로 포함하는 비알코올성 지방간 예방 또는 치료용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101225566B1 (ko) * | 2011-08-11 | 2013-01-23 | 유상기 | 여성 갱년기 증상 개선용 기능성 식품 조성물 |
KR20150037208A (ko) * | 2013-09-30 | 2015-04-08 | 재단법인 전남생물산업진흥원 | 여성 폐경기 증후군 치료용 조성물 |
CN104887693A (zh) * | 2015-05-07 | 2015-09-09 | 中国科学院深圳先进技术研究院 | 治疗骨质疏松症的药物组合物及其脂质体制剂和制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04502145A (ja) | 1988-06-24 | 1992-04-16 | ウエスタン ホールデイング カンパニー リミテツド | テルペンのオゾニドおよびその医療的使用 |
JP4312402B2 (ja) * | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
JP2007246470A (ja) * | 2006-03-17 | 2007-09-27 | Daicho Kikaku:Kk | 新しい薬剤 |
CN1876096A (zh) * | 2006-04-21 | 2006-12-13 | 韩志强 | 治疗妇女更年期综合症中药胶囊主药组分及其制备方法 |
CN101085146A (zh) | 2006-06-07 | 2007-12-12 | 西安量维纳米时代实业有限公司 | 一种蜂胶熟地的组合物及其制备工艺与应用 |
CN101757410A (zh) | 2008-10-29 | 2010-06-30 | 天津金世制药有限公司 | 一种治疗更年期综合症的中药组合物及其制备方法 |
MX2011005835A (es) | 2008-12-26 | 2011-07-04 | Natural Endotech Co Ltd | Composiciones fitoestrogenicas para prevenir o tratar los sintomas asociados con la menopausia. |
CN101658626A (zh) | 2009-05-20 | 2010-03-03 | 北京国奥健康科技研究院 | 治疗抑郁症的中药制剂 |
CN102824400B (zh) | 2011-07-28 | 2015-01-07 | 天津中医药大学 | 包含杜仲和续断的组合物及其治疗骨质疏松症的用途 |
CN103110651A (zh) | 2013-02-06 | 2013-05-22 | 南京中医药大学 | 山茱萸中有效成分马钱苷在制备治疗糖尿病药物中的应用 |
KR20150024651A (ko) | 2013-08-27 | 2015-03-09 | 동아대학교 산학협력단 | 로가닌을 유효성분으로 포함하는 퇴행성 신경질환 예방 또는 치료용 조성물 |
KR20150038906A (ko) * | 2013-10-01 | 2015-04-09 | 주식회사한국전통의학연구소 | 생약 추출물을 포함하는 후기 발현 남성 성선기능저하증 내지 남성갱년기 증후군 예방 또는 치료용 조성물 및 건강 기능성 식품 |
CN104706704B (zh) | 2015-02-09 | 2018-01-19 | 江苏海王健康生物科技有限公司 | 玛咖组合物、其复方制剂及其应用 |
-
2016
- 2016-01-13 KR KR1020160004169A patent/KR101698051B1/ko active IP Right Grant
-
2017
- 2017-01-13 JP JP2018556775A patent/JP6818047B2/ja active Active
- 2017-01-13 RU RU2018128198A patent/RU2697672C1/ru active
- 2017-01-13 WO PCT/KR2017/000438 patent/WO2017123030A1/ko active Application Filing
- 2017-01-13 AU AU2017206480A patent/AU2017206480B2/en active Active
- 2017-01-13 CA CA3021083A patent/CA3021083C/en active Active
- 2017-01-13 US US16/069,522 patent/US11116781B2/en active Active
- 2017-01-13 CN CN201780016721.3A patent/CN109069524A/zh active Pending
- 2017-01-13 BR BR112018014254-9A patent/BR112018014254A2/ko active Search and Examination
- 2017-01-13 EP EP17738659.6A patent/EP3403656B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101225566B1 (ko) * | 2011-08-11 | 2013-01-23 | 유상기 | 여성 갱년기 증상 개선용 기능성 식품 조성물 |
KR20150037208A (ko) * | 2013-09-30 | 2015-04-08 | 재단법인 전남생물산업진흥원 | 여성 폐경기 증후군 치료용 조성물 |
CN104887693A (zh) * | 2015-05-07 | 2015-09-09 | 中国科学院深圳先进技术研究院 | 治疗骨质疏松症的药物组合物及其脂质体制剂和制备方法 |
Non-Patent Citations (3)
Title |
---|
LI, M. ET AL.: "The Pharmacological Effects of Morroniside and Loganin Isolated from Liuweidihuang Wan, onMC3T3-El Cells", MOLECULES, vol. 15, 2010, pages 7403 - 7414, XP055400553 * |
PARK JIN-HYEOK: "Development of Functional Foods Having an Effect on Prevention and Improvement of Osteoporosis via Regulating the Key Gene Expression Associated with Bone Metabolism", DONGWOODANG PHARMACY CO., LTD., 2015, pages 1 - 115, XP009513503 * |
See also references of EP3403656A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107485617A (zh) * | 2017-08-08 | 2017-12-19 | 中日友好医院 | 马钱苷在制备治疗或缓解疼痛的药物和保健品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3403656A1 (en) | 2018-11-21 |
US11116781B2 (en) | 2021-09-14 |
KR101698051B1 (ko) | 2017-01-20 |
AU2017206480A1 (en) | 2018-08-30 |
RU2697672C1 (ru) | 2019-08-16 |
CA3021083A1 (en) | 2017-07-20 |
CN109069524A (zh) | 2018-12-21 |
US20190000869A1 (en) | 2019-01-03 |
CA3021083C (en) | 2021-06-15 |
AU2017206480B2 (en) | 2020-01-23 |
JP2019503399A (ja) | 2019-02-07 |
JP6818047B2 (ja) | 2021-01-20 |
EP3403656B1 (en) | 2023-06-28 |
EP3403656A4 (en) | 2019-09-18 |
BR112018014254A2 (ko) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017123030A1 (ko) | 로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 갱년기 증후군 예방, 개선 또는 치료용 조성물 | |
KR20090094437A (ko) | 상승-약량 연장 주기 요법을 이용한 호르몬 치료 방법 | |
JPH0680017B2 (ja) | 抗エストロゲンと担体よりなる組成物の製法 | |
JP2000516576A (ja) | エストロゲン―アンドロゲン―プロゲスチンの組み合わせによる医薬品としての経口避妊薬 | |
JP2004155779A (ja) | 更年期症の予防・治療用経口組成物 | |
KR101141194B1 (ko) | 폐경기 증상의 예방 또는 치료용 식물성에스트로겐 조성물 | |
US9333184B2 (en) | Composition and method for affecting male and female hormone levels | |
Maddox | Women at midlife: Hormone replacement therapy | |
EA008057B1 (ru) | Способы ингибирования ускоренного созревания эндометрия у женщины и самки млекопитающего кроме человека и способы достижения состояния беременности у женщины и самки млекопитающего кроме человека | |
US11464817B2 (en) | Composition for preventing, improving or treating female menopausal disease | |
HUT64848A (en) | Medical preparatives for preventing and treating osteoporises after menopausa | |
WO2008004223A2 (en) | Compounds and methods for the treatment of menopause and bone related disorders | |
WO2017123031A1 (ko) | 로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 폐경 후 골다공증 예방, 개선 또는 치료용 조성물 | |
US20150031775A1 (en) | Composition and method for affecting male and female hormone levels | |
KR101739838B1 (ko) | 로가닌을 유효성분으로 함유하는 파골세포 분화 억제용 시약 조성물 | |
WO2018190631A1 (ko) | 번행초 추출물을 유효성분으로 함유하는 에스트로겐 분비 저하에 의한 우울증의 예방, 개선 또는 치료용 조성물 | |
US9339458B2 (en) | Use of vaginal insulin sensitizing agents | |
US11058737B2 (en) | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females | |
RU2812129C1 (ru) | Гормональное средство для регуляции половой охоты у мелких домашних животных | |
KR101756405B1 (ko) | 스코폴린을 유효성분으로 함유하는 여성 폐경 후 골다공증 예방 또는 개선용 조성물 | |
CN108853007B (zh) | 一种治疗功能性子宫出血的凝胶制剂及其用途 | |
KR101759477B1 (ko) | 스코폴린을 유효성분으로 함유하는 여성 폐경 후 골다공증 예방 또는 치료용 조성물 | |
CN106902102A (zh) | 玛咖酰胺类化合物在制备治疗月经不调药物中的应用 | |
DK2399583T3 (en) | The use of insulin-sensitizing agents administered vaginally | |
US20170252363A1 (en) | Composition for preventing, improving or treating postmenopausal osteoporosis comprising scopolin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17738659 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018556775 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018014254 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017738659 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017738659 Country of ref document: EP Effective date: 20180813 |
|
ENP | Entry into the national phase |
Ref document number: 2017206480 Country of ref document: AU Date of ref document: 20170113 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3021083 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 112018014254 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180712 |